Onkológia S3/2018

Successful treatment of pomalidomide in ordinary relaps multiple myeloma

Purpose: Multiple myeloma treatment has undergone significant changes in the past twenty years. The introduction of new therapies and procedures into common clinical practice - bortezomib, lenalidomide, autologous bone marrow transplantation significantly prolonged overall survival. However, all patients relapse gradually, and additional treatment options are needed. One of them is pomalidomide, a second-generation immunomodulatory treatment with a direct antiproliferative effect. Case: In our case, we present a patient with multiple myeloma, repeatedly relapsed during treatment, which was begun in 2002. The patient underwent autologous bone marrow transplantation twice, with lenalidomide and bortezomib repeatedly. For signs of refractoriness on these treatments, the patient has been treated with pomalidomide with partial remission and a significant prolongation of overall survival since 2015. Conclusion: Multiple myeloma treatment is evolving, dream medication is coming, and appropriate drug combinations are sought to achieve the best clinical results. Appropriate treatment strategies can achieve long-term disease control and prolong overall survival.

Keywords: multiple myeloma, pomalidomide, lenalidomide, bortezomib